Almirall

Homepage URL: almirall.com

Alternate names: Almirall SA, Almirall, S.A.

Description: Pharmaceutical company

Country: ES

ROR: 03qsven24

Wikidata ID: wiki/Q944760

Crossref ID: 501100022606

DOI: 10.13039/501100022606

OpenAlex ID: F4320331744

The mental health risks of economic crisis in Spain: evidence from primary care centres, 2006 and 2010

2012 · Margalida Gili, Miquel Roca, et al. · European Journal of Public Health · 640

PDF

Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches

2017 · Zoe Apalla, Dorothée Nashan, et al. · Dermatology and Therapy · 502

PDF

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

2020 · Alexander J. Stratigos, Claus Garbe, et al. · European Journal of Cancer · 331

PDF

Chitosan–PEG nanocapsules as new carriers for oral peptide delivery

2006 · C. Prego, D. Torres, et al. · Journal of Controlled Release · 312

Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis

2020 · Anne-Sofie Halling, Nikolai Loft, et al. · Journal of the American Academy of Dermatology · 301

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

2019 · Jonathan I. Silverberg, Andreas Pinter, et al. · Journal of Allergy and Clinical Immunology · 277

PDF

Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

2018 · Cristina Tassorelli, Licia Grazzi, et al. · Neurology · 265

PDF

Actinic keratosis with atypical basal cells ( AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin

2014 · M.T. Fernández‐Figueras, C. Carrato, et al. · Journal of the European Academy of Dermatology and Venereology · 240

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019

2019 · Claus Garbe, Teresa Amaral, et al. · European Journal of Cancer · 221

Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

2017 · AB-GEN Collaborative Group, Víctor Pérez, et al. · BMC Psychiatry · 213

PDF

Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy: Patients Ineligible vs Eligible for Randomized Controlled Trials

2012 · Gregorio Carretero · Archives of Dermatology · 204

PDF

Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies

2015 · T. Tzellos, C.C. Zouboulis, et al. · British Journal of Dermatology · 200

Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study

2014 · Marc Miravitlles, Heinrich Worth, et al. · Respiratory Research · 199

PDF

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

2020 · Eric Simpson, Robert Bissonnette, et al. · Journal of the American Academy of Dermatology · 193

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*

2020 · I.Y.K. Iskandar, R. Parisi, et al. · British Journal of Dermatology · 192

PDF

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

2023 · Andrew Blauvelt, Jacob P Thyssen, et al. · British Journal of Dermatology · 178

PDF

The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature

2019 · Ana B. Pavel, Lisa Zhou, et al. · Journal of the American Academy of Dermatology · 170

A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery

2005 · M. Garcia-Fuentes, C. Prego, et al. · European Journal of Pharmaceutical Sciences · 170

New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin

2005 · M GARCIAFUENTES, D TORRES, et al. · International Journal of Pharmaceutics · 164

Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

2018 · Jolana Markovà, Ute Essner, et al. · International Journal of Neuroscience · 158

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

2018 · Antoni Torres, Catia Cillóniz, et al. · Respiratory Medicine · 158

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE)

2016 · U. Mrowietz, J.C. Szepietowski, et al. · British Journal of Dermatology · 156

PDF

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

2019 · K. Reich, R.B. Warren, et al. · British Journal of Dermatology · 152

PDF

Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD

2013 · Henry Chrystyn, Mark Small, et al. · Respiratory Medicine · 151

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

2014 · Anthony D D’Urzo, Stephen I Rennard, et al. · Respiratory Research · 148

PDF

Works count: 386

Citation count: 12,790

H-index: 60

I10-index: 194

2-year mean citedness: 3.64

Awards count: 8